Find in Library

Background: Type 2 diabetes mellitus is one of the leading causes of morbidity and mortality worldwide and is derived from an accumulation of genetic and epigenetic changes. In this study, we aimed to construct Insilco, a competing endogenous RNA (ceRNA) network linked to the pathogenesis of insulin resistance followed by its experimental validation in patients’, matched control and cell line samples, as well as to evaluate the efficacy of CRISPR/Cas9 as a potential therapeutic strategy to modulate the expression of this deregulated network. By applying bioinformatics tools through a two-step process, we identified and verified a ceRNA network panel of mRNAs, miRNAs and lncRNA related to insulin resistance, Then validated the expression in clinical samples (123 patients and 106 controls) and some of matched cell line samples using real time PCR. Next, two guide RNAs were designed to target the sequence flanking LncRNA/miRNAs interaction by CRISPER/Cas9 in cell culture. Gene editing tool efficacy was assessed by measuring the network downstream proteins <i>GLUT4</i> and <i>mTOR</i> via immunofluorescence. Results: <i>LncRNA-RP11-773H22.4</i>, together with <i>RET</i>, <i>IGF1R</i> and <i>mTOR mRNAs</i>, showed significant upregulation in T2DM compared with matched controls, while miRNA (i.e., <i>miR-3163 and miR-1</i>) and mRNA (i.e., <i>GLUT4</i> and <i>AKT2</i>) expression displayed marked downregulation in diabetic samples. CRISPR/Cas9 successfully knocked out <i>LncRNA-RP11-773H22.4</i>, as evidenced by the reversal of the gene expression of the identified network at RNA and protein levels to the normal expression pattern after gene editing. Conclusions: The present study provides the significance of this ceRNA based network and its related target genes panel both in the pathogenesis of insulin resistance and as a therapeutic target for gene editing in T2DM.